Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature
Abstract
1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Griffiths, C.E.M.; Armstrong, A.W.; Gudjonsson, J.E.; Barker, J.N.W.N. Psoriasis. Lancet 2021, 397, 1301–1315. [Google Scholar] [CrossRef] [PubMed]
- Rendon, A.; Schäkel, K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019, 20, 1475. [Google Scholar] [CrossRef] [PubMed]
- Sbidian, E.; Chaimani, A.; Garcia-Doval, I.; Doney, L.; Dressler, C.; Hua, C.; Hughes, C.; Naldi, L.; Afach, S.; Le Cleach, L. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Emergencias 2022, 2022, CD011535. [Google Scholar] [CrossRef] [PubMed]
- Blauvelt, A.; Chiricozzi, A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin. Rev. Allergy Immunol. 2018, 55, 379–390. [Google Scholar] [CrossRef] [PubMed]
- Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; et al. Secukinumab in Plaque Psoriasis—Results of Two Phase 3 Trials. N. Engl. J. Med. 2014, 371, 326–338. [Google Scholar] [CrossRef] [PubMed]
- Lebwohl, M.; Strober, B.; Menter, A.; Gordon, K.; Weglowska, J.; Puig, L.; Papp, K.; Spelman, L.; Toth, D.; Kerdel, F.; et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N. Engl. J. Med. 2015, 373, 1318–1328. [Google Scholar] [CrossRef]
- Gordon, K.B.; Blauvelt, A.; Papp, K.A.; Langley, R.G.; Luger, T.; Ohtsuki, M.; Reich, K.; Amato, D.; Ball, S.G.; Braun, D.K.; et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N. Engl. J. Med. 2016, 375, 345–356. [Google Scholar] [CrossRef] [PubMed]
- Kolbinger, F.; Loesche, C.; Valentin, M.-A.; Jiang, X.; Cheng, Y.; Jarvis, P.; Peters, T.; Calonder, C.; Bruin, G.; Polus, F.; et al. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis. J. Allergy Clin. Immunol. 2017, 139, 923–932.e8. [Google Scholar] [CrossRef]
- Glatt, S.; Baeten, D.; Baker, T.; Griffiths, M.; Ionescu, L.; Lawson, A.D.G.; Maroof, A.; Oliver, R.; Popa, S.; Strimenopoulou, F.; et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann. Rheum. Dis. 2018, 77, 523–532. [Google Scholar] [CrossRef]
- Qiu, Y.; Zhu, Y.; Liu, Y.; Liu, Q. Efficacy and safety of bimekizumab for the treatment of psoriasis: A systematic review and meta-analysis of randomized clinical trials. J. Dermatol. Treat. 2023, 34, 2199106. [Google Scholar] [CrossRef]
- McInnes, I.B.; Asahina, A.; Coates, L.C.; Landewé, R.; Merola, J.F.; Ritchlin, C.T.; Tanaka, Y.; Gossec, L.; Gottlieb, A.B.; Warren, R.B.; et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 2023, 401, 25–37. [Google Scholar] [CrossRef] [PubMed]
- Merola, J.F.; Landewé, R.; McInnes, I.B.; Mease, P.J.; Ritchlin, C.T.; Tanaka, Y.; Asahina, A.; Behrens, F.; Gladman, D.D.; Gossec, L.; et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 2023, 401, 38–48. [Google Scholar] [CrossRef] [PubMed]
- Van Der Heijde, D.; Deodhar, A.; Baraliakos, X.; Brown, M.A.; Dobashi, H.; Dougados, M.; Elewaut, D.; Ellis, A.M.; Fleurinck, C.; Gaffney, K.; et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: Results of two parallel phase 3 randomised controlled trials. Ann. Rheum. Dis. 2023, 82, 515–526. [Google Scholar] [CrossRef] [PubMed]
- Glatt, S.; Jemec, G.B.; Forman, S.; Sayed, C.; Schmieder, G.; Weisman, J.; Rolleri, R.; Seegobin, S.; Baeten, D.; Ionescu, L.; et al. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. JAMA Dermatol. 2021, 157, 1279–1288. [Google Scholar] [CrossRef]
- Kontzias, C.; Chandy, R.; Feldman, S.R. Choosing Systemic Agents for Psoriasis. Ann. Pharmacother. 2024, 58, 333–337. [Google Scholar] [CrossRef] [PubMed]
- Don, B.R.; Spin, G.; Rose, A.; Nestorov, I.; Hutmacher, M.; A Kaysen, G. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J. Pharm. Pharmacol. 2010, 57, 1407–1413. [Google Scholar] [CrossRef] [PubMed]
- Mukai, M.; Kurihara, Y.; Ito, Y.; Shintani, Y.; Takahashi, H.; Kubo, A.; Amagai, M.; Umegaki-Arao, N. Successful treatment with secukinumab of three psoriatic patients undergoing dialysis. J. Dermatol. 2020, 47, E26–E28. [Google Scholar] [CrossRef] [PubMed]
- Koike, Y.; Fujiki, Y.; Higuchi, M.; Fukuchi, R.; Kuwatsuka, S.; Murota, H. An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. JAAD Case Rep. 2019, 5, 150–152. [Google Scholar] [CrossRef] [PubMed]
- Ishibashi, M.; Shiiyama, R. A Case of Psoriasis Vulgaris Treated with Brodalumab in a Hemodialysis Patient with End-Stage Renal Disease due to Diabetic Nephropathy. Case Rep. Dermatol. Med. 2020, 2020, 3863152–3863154. [Google Scholar] [CrossRef]
- Larquey, M.; Girard, C.; Sbidian, E.; Richard, M.-A.; Aubin, F.; Schmutz, J.-L. Efficacy of biologics in psoriasis patients under hemodialysis. Eur. J. Dermatol. 2017, 27, 531–533. [Google Scholar] [CrossRef]
- Yamamoto, T.; Yokozeki, H.; Nishioka, K. Psoriasis under haemodialysis. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 1139–1140. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.; Tang, C.; Huang, K.; Huang, S.; Sue, Y. Increased risk of incident psoriasis in end-stage renal disease patients on chronic hemodialysis: A nationwide population-based cohort study. J. Dermatol. 2018, 45, 1063–1070. [Google Scholar] [CrossRef]
- Wild, J.; Keller, K.; Karbach, S.; Weinmann-Menke, J.; Münzel, T.; Hobohm, L. Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease. J. Clin. Med. 2022, 11, 4328. [Google Scholar] [CrossRef] [PubMed]
- Mele, C.; Salerno, M.; Romagnoli, J.; De Simone, C.; Castriota, M.; Citterio, F. Complete Clinical Remission of Psoriasis 6 Months After Renal Transplantation. Transplant. Proc. 2013, 45, 2788–2789. [Google Scholar] [CrossRef] [PubMed]
- Schwade, M.J.; Tien, L.; Waller, J.L.; Davis, L.S.; Baer, S.L.; Mohammed, A.; Young, L.; Kheda, M.F.; Bollag, W.B. Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: A retro-spective cohort study. Am. J. Med. Sci. 2021, 362, 24–33. [Google Scholar] [CrossRef]
- Bustos, B.d.U.; Sánchez, R.B.; Martínez, V.O.; Carazo, J.L.S. Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis. Int. J. Dermatol. 2014, 53, e299–e301. [Google Scholar] [CrossRef]
- Cassano, N.; Vena, G.A. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int. J. Dermatol. 2008, 47, 980–981. [Google Scholar] [CrossRef]
- Ikuma, D.; Oguro, M.; Hoshino, J.; Mizuno, H.; Sekine, A.; Kawada, M.; Hiramatsu, R.; Sumida, K.; Hasegawa, E.; Hayami, N.; et al. Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis. CEN Case Rep. 2020, 9, 55–58. [Google Scholar] [CrossRef]
- Kusakari, Y.; Yamasaki, K.; Takahashi, T.; Tsuchiyama, K.; Shimada-Omori, R.; Nasu-Tamabuchi, M.; Aiba, S. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. J. Dermatol. 2015, 42, 727–730. [Google Scholar] [CrossRef]
- Larquey, M.; Poreaux, C.; Cuny, J.-F.; Barbaud, A.; Schmutz, J.-L. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis. Eur. J. Dermatol. 2014, 24, 618–619. [Google Scholar] [CrossRef]
- Nimmannitya, K.; Tateishi, C.; Mizukami, Y.; Hamamoto, K.; Yamada, S.; Goto, H.; Okada, S.; Tsuruta, D. Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis. J. Dermatol. 2016, 43, 92–94. [Google Scholar] [CrossRef] [PubMed]
- Pizzatti, L.; Mugheddu, C.; Sanna, S.; Atzori, L.; Rongioletti, F. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol. Ther. 2020, 33, e13348. [Google Scholar] [CrossRef] [PubMed]
- Saougou, I.; Papagoras, C.; Markatseli, T.E.; Voulgari, P.V.; Drosos, A.A. A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. Clin. Rheumatol. 2010, 29, 1455–1459. [Google Scholar] [CrossRef] [PubMed]
- Shibata, T.; Muto, J.; Takama, H.; Yanagishita, T.; Ito, T.; Watanabe, D. Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab. J. Dermatol. 2019, 46, e119–e120. [Google Scholar] [CrossRef]
- Umezawa, Y.; Hayashi, M.; Kikuchi, S.; Fukuchi, O.; Yanaba, K.; Ito, T.; Asahina, A.; Saeki, H.; Nakagawa, H. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J. Dermatol. 2015, 42, 731–734. [Google Scholar] [CrossRef]
Author | Year | Treatment | PASI T0 | PASI T1 | Follow-Up | Psoriatic Arthritis | Previous Therapies | Additional Info | Adverse Events |
---|---|---|---|---|---|---|---|---|---|
Bustos et al. [26] | 2014 | Ustekinumab | 15 | 0 | 17 months | no | Methotrexate, cyclosporine, acitretin, phototherapy, Etanercept | hypertension, ischemic heart disease, and chronic renal failure four years ago | No |
Cassano et al. [27] | 2008 | Etanercept | 21 | 0.8 | 6 months | yes (effective) | Topical, phototherapy, cyclosporine | HD since 9 years, atrial fibrillation; asymptomatic HCV infection | No |
Ikuma et al. [28] | 2019 | Secukinumab | 49.8 | 14.8 | 28 months | no | Topical | HD since 39 y.o. | No |
Ishiabashi et al. [19] | 2019 | Brodalumab | 39.6 | 0 | 12 months | no | Cyclosporine | HD since 2 months; diabetes | Chronic cough |
Koike et al. [18] | 2019 | Ixekizumab | 21.6 | 0 | 18 months | yes | none | HD since 4 year, HBV carrier; improvement of the psoriatic arthritis | No |
Kusakari et al. [29] | 2015 | Adalimumab | 42.3 | 0 | 12 months | no | Cyclosporine, infliximab (AE), ustekinumab (no improvement) | Pulmonary edema because of hydration during the i.v. injection of infliximab | No |
Larquey et al. [20] | 2017 | Adalimumab | - | - | - | no | - | - | No |
Larquey et al. [20] | 2017 | Etanercept | - | - | - | no | - | - | No |
Larquey et al. [20] | 2017 | Etanercept | - | - | - | no | - | - | No |
Larquey et al. [20] | 2017 | Etanercept | - | - | - | no | - | - | No |
Larquey et al. [30] | 2014 | Ustekinumab | 13.6 | 4.5 | 9 months | no | Topical | HD since 7 years, obesity | No |
Larquey et al. [20] | 2017 | Ustekinumab | - | - | - | no | - | - | No |
Mukai et al. [17] | 2019 | Secukinumab | 33 | 3.3 | 5 months | yes | Phototherapy | Peritoneal dyalisis since 12 years | No |
Mukai et al. [17] | 2019 | Secukinumab | 31 | 3.1 | 4 months | no | Phototherapy | - | No |
Mukai et al. [17] | 2019 | Secukinumab | - | - | - | yes (effective) | Cyclosporine | - | No |
Nimmanitya et al. [31] | 2016 | Ustekinumab | 15.4 | 2.8 | 33 months | no | Topical, phototherapy | Policystic kidney disease | No |
Pizzatti et al. [32] | 2020 | Secukinumab | 31.5 | 0 | 12 months | no | Cyclosporine, phototherapy | - | No |
Saougu et al. [33] | 2010 | Infliximab | 35.1 | 0 | 6 months | yes (effective) | none | improvement of the psoriatic arthritis | No |
Shibata et al. [34] | 2018 | Secukinumab | 22 | 0 | 24 months | no | Topical, oral corticosteroids | - | No |
Umezawa et al. [35] | 2015 | Ustekinumab | 10.4 | 0 | 12 months | no | Topical | HD since 10 years | No |
Umezawa et al. [35] | 2015 | Ustekinumab | 12.4 | 3 | 12 months | no | Topical | HD since 10 years | No |
Umezawa et al. [35] | 2015 | Ustekinumab | 17.2 | 2 | 12 months | no | Topical, phototherapy | HD since 1 year | No |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bernardini, N.; Ambrosio, L.; Tolino, E.; Proietti, I.; Skroza, N.; Potenza, C. Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature. J. Clin. Med. 2024, 13, 2250. https://doi.org/10.3390/jcm13082250
Bernardini N, Ambrosio L, Tolino E, Proietti I, Skroza N, Potenza C. Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature. Journal of Clinical Medicine. 2024; 13(8):2250. https://doi.org/10.3390/jcm13082250
Chicago/Turabian StyleBernardini, Nicoletta, Luca Ambrosio, Ersilia Tolino, Ilaria Proietti, Nevena Skroza, and Concetta Potenza. 2024. "Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature" Journal of Clinical Medicine 13, no. 8: 2250. https://doi.org/10.3390/jcm13082250
APA StyleBernardini, N., Ambrosio, L., Tolino, E., Proietti, I., Skroza, N., & Potenza, C. (2024). Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature. Journal of Clinical Medicine, 13(8), 2250. https://doi.org/10.3390/jcm13082250